New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:32 EDTDYAXDyax shares should be bought, says RBC Capital
After meeting with Dyax's management, RBC Capital thinks sales of the company's Kalbitor drug may surpass expectations in Q2, while the company could start talking on its Q2 conference call about new indications for the drug that investors haven't considered. The firm believes that the company has a number of potential positive catalysts from upcoming clinical trials, and it keeps a $15 price target and Outperform rating on the shares.
News For DYAX From The Last 14 Days
Check below for free stories on DYAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for DYAX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use